Becton, Dickinson Italia S.P.A.

Becton, Dickinson Italia S.P.A. is an Italian-based subsidiary of the global medical technology company Becton, Dickinson and Company, a manufacturer of medical devices, diagnostic equipment, and related laboratory products. As a for-profit organization registered in SAM.gov since April 27, 2010, the company specializes in providing microbiological and bacteriological diagnostic testing products and consumables to support U.S. military medical facilities abroad. The entity operates as a manufacturer of goods and leverages its Italian operations to ensure efficient delivery of critical laboratory diagnostic supplies to overseas U.S. defense health installations, particularly those requiring automated diagnostic testing capabilities.

Becton, Dickinson Italia S.P.A. has demonstrated consistent performance through multiple federal contract awards totaling approximately $600,000 in cumulative contract value since 2021, all awarded without small business set-aside designations. The company has provided BD MAX System consumables, microbiological and bacteriological culture products compatible with the BD MAX automated diagnostic platform, and microbiology media plates through delivery orders, purchase orders, and blanket purchase agreement calls. Awards have been issued by the Defense Health Agency and the Department of the Army Medical Command, supporting laboratory diagnostic operations at U.S. military treatment facilities in Italy, including the U.S. Army Health Center in Vicenza and U.S. Navy Hospital testing operations. The vendor has also provided maintenance services for the BD MAX automated microbiology analyzer system, including a full-risk maintenance services contract with Option Year 3 exercised through May 31, 2027. All contracts were firm fixed-price awards with performance conducted in Italy, reflecting the specialized nature of the diagnostic testing products and the vendor's established manufacturing and distribution capabilities in supporting military healthcare readiness.

Becton, Dickinson Italia S.P.A. currently holds a single-award Blanket Purchase Agreement with the Defense Health Agency valued at $249,000, effective March 1, 2024 through February 28, 2029. This BPA covers microbiological and bacteriological culture products compatible with the BD MAX automated diagnostic platform and serves as the parent vehicle for multiple task orders awarded to the company. To date, the BPA has generated approximately $290,000 in task order awards, exceeding the ceiling value and demonstrating sustained demand for the company's diagnostic testing products at military medical treatment facilities. Documented BPA calls include orders valued at $45,728.29 awarded March 1, 2024, $16,162.05 awarded March 1, 2025, $50,321.53 awarded October 1, 2025, and $108,255.63 awarded October 1, 2024, all supporting BD MAX System consumables and microbiological culture products. The Defense Health Agency's continued reliance on this BPA vehicle reflects the vendor's proven capability in fulfilling specialized federal requirements for laboratory diagnostic products essential to military medical operations and demonstrates the critical role these consumables play in enabling rapid microbiological identification and susceptibility testing in military healthcare settings.